Skip to main content
Erschienen in: Journal of Interventional Cardiac Electrophysiology 3/2024

12.09.2023

Accuracy of symptoms and pulse checking for detecting atrial fibrillation following catheter ablation

verfasst von: Timothy M. Markman, Carli Peters, Simone Tate, Gustavo S. Guandalini, Matthew C. Hyman, Robert D. Schaller, Gregory E. Supple, Michael P. Riley, Fermin Garcia, Saman Nazarian, David Lin, Sanjay Dixit, Andrew E. Epstein, David J. Callans, Francis E. Marchlinski, David S. Frankel

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

There is growing interest in the possibility of discontinuing oral anticoagulation following successful catheter ablation of atrial fibrillation (AF). However, it remains unknown whether patients can accurately detect arrhythmia recurrences following ablation. We therefore sought to characterize the accuracy of pulse checking and arrhythmia symptoms for the identification of AF following ablation.

Methods

This prospective cohort study included patients at the Hospital of the University of Pennsylvania with an insertable cardiac monitor (ICM) treated with catheter ablation for AF who recorded the results from minimum twice daily pulse checks and additionally with arrhythmia symptoms into a diary for 2 months following their procedure. Accuracy of this self-assessment protocol was determined by comparison to ICM-detected AF.

Results

A total of 55 patients (age 69 ± 8 years, 30 (55%) male, CHA2DS2VASc score 3.2 ± 1. 5) were included. Patients recorded a total of 5911 pulse checks, and there were 280 episodes of ICM-documented AF among 26 patients with an average duration of 2.5 ± 3.3 h. Among 362 episodes of patient-suspected AF, 134 correlated with ICM-identified AF (37% true positive rate). Of the 5549 pulse checks that did not identify AF, 196 correlated with ICM-identified AF (4% false negative rate). Twice daily pulse checking had a sensitivity of 47% and a specificity of 96% for identifying each episode of AF.

Conclusions

Our data indicate that a strategy of pulse checks and symptom assessment is insufficient to identify all episodes of AF in many patients following catheter ablation.
Literatur
1.
Zurück zum Zitat Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol. 2000;36:1303–9.CrossRefPubMed Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol. 2000;36:1303–9.CrossRefPubMed
2.
Zurück zum Zitat Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.CrossRefPubMed Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.CrossRefPubMed
3.
Zurück zum Zitat Szucs TD, Bramkamp M. Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. J Thromb Haemost. 2006;4:1180–5.CrossRefPubMed Szucs TD, Bramkamp M. Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. J Thromb Haemost. 2006;4:1180–5.CrossRefPubMed
4.
Zurück zum Zitat Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2021;384:305–15.CrossRefPubMed Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2021;384:305–15.CrossRefPubMed
5.
Zurück zum Zitat Kumagai K, Toyama H, Zhang B. Effects of additional ablation of low-voltage areas after box isolation for persistent atrial fibrillation. J Arrhythm. 2019;35:197–204.CrossRefPubMedPubMedCentral Kumagai K, Toyama H, Zhang B. Effects of additional ablation of low-voltage areas after box isolation for persistent atrial fibrillation. J Arrhythm. 2019;35:197–204.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Bunch TJ, May HT, Bair TL, et al. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm. 2013;10:1272–7.CrossRefPubMed Bunch TJ, May HT, Bair TL, et al. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm. 2013;10:1272–7.CrossRefPubMed
7.
Zurück zum Zitat Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321:1261–74.CrossRefPubMedPubMedCentral Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321:1261–74.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Passman R, Bernstein RA. New appraisal of atrial fibrillation burden and stroke prevention. Stroke. 2016;47:570–6.CrossRefPubMed Passman R, Bernstein RA. New appraisal of atrial fibrillation burden and stroke prevention. Stroke. 2016;47:570–6.CrossRefPubMed
9.
Zurück zum Zitat Tiver KD, Quah J, Lahiri A, Ganesan AN, McGavigan AD. Atrial fibrillation burden: an update-the need for a CHA2DS2-VASc-AFBurden score. Europace. 2021;23:665–73.CrossRefPubMed Tiver KD, Quah J, Lahiri A, Ganesan AN, McGavigan AD. Atrial fibrillation burden: an update-the need for a CHA2DS2-VASc-AFBurden score. Europace. 2021;23:665–73.CrossRefPubMed
10.
Zurück zum Zitat January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74:104–32.CrossRefPubMed January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74:104–32.CrossRefPubMed
11.
Zurück zum Zitat Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373–498.CrossRefPubMed Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373–498.CrossRefPubMed
12.
Zurück zum Zitat Karasoy D, Gislason GH, Hansen J, et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark. Eur Heart J. 2015;36:307–14.CrossRefPubMed Karasoy D, Gislason GH, Hansen J, et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark. Eur Heart J. 2015;36:307–14.CrossRefPubMed
13.
Zurück zum Zitat Freeman JV, Shrader P, Pieper KS, et al. Outcomes and anticoagulation use after catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2019;12:e007612.CrossRefPubMed Freeman JV, Shrader P, Pieper KS, et al. Outcomes and anticoagulation use after catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2019;12:e007612.CrossRefPubMed
14.
Zurück zum Zitat Sjalander S, Holmqvist F, Smith JG, et al. Assessment of use vs discontinuation of oral anticoagulation after pulmonary vein isolation in patients with atrial fibrillation. JAMA Cardiol. 2017;2:146–52.CrossRefPubMed Sjalander S, Holmqvist F, Smith JG, et al. Assessment of use vs discontinuation of oral anticoagulation after pulmonary vein isolation in patients with atrial fibrillation. JAMA Cardiol. 2017;2:146–52.CrossRefPubMed
15.
Zurück zum Zitat Noseworthy PA, Yao X, Deshmukh AJ et al. Patterns of anticoagulation use and cardioembolic risk after catheter ablation for atrial fibrillation. J Am Heart Assoc. 2015;4:e002597. Noseworthy PA, Yao X, Deshmukh AJ et al. Patterns of anticoagulation use and cardioembolic risk after catheter ablation for atrial fibrillation. J Am Heart Assoc. 2015;4:e002597.
16.
Zurück zum Zitat Deng L, Xiao Y, Hong H. Withdrawal of oral anticoagulants 3 months after successful radiofrequency catheter ablation in patients with atrial fibrillation: a meta-analysis. Pacing Clin Electrophysiol. 2018;41:1391–400.CrossRefPubMed Deng L, Xiao Y, Hong H. Withdrawal of oral anticoagulants 3 months after successful radiofrequency catheter ablation in patients with atrial fibrillation: a meta-analysis. Pacing Clin Electrophysiol. 2018;41:1391–400.CrossRefPubMed
17.
Zurück zum Zitat Hermans ANL, Gawalko M, Pluymaekers N, et al. Long-term intermittent versus short continuous heart rhythm monitoring for the detection of atrial fibrillation recurrences after catheter ablation. Int J Cardiol. 2021;329:105–12.CrossRefPubMed Hermans ANL, Gawalko M, Pluymaekers N, et al. Long-term intermittent versus short continuous heart rhythm monitoring for the detection of atrial fibrillation recurrences after catheter ablation. Int J Cardiol. 2021;329:105–12.CrossRefPubMed
18.
Zurück zum Zitat Hanke T, Charitos EI, Stierle U, et al. Twenty-four-hour holter monitor follow-up does not provide accurate heart rhythm status after surgical atrial fibrillation ablation therapy: up to 12 months experience with a novel permanently implantable heart rhythm monitor device. Circulation. 2009;120:S177–84.CrossRefPubMed Hanke T, Charitos EI, Stierle U, et al. Twenty-four-hour holter monitor follow-up does not provide accurate heart rhythm status after surgical atrial fibrillation ablation therapy: up to 12 months experience with a novel permanently implantable heart rhythm monitor device. Circulation. 2009;120:S177–84.CrossRefPubMed
19.
Zurück zum Zitat Unni RR, Prager RT, Odabashian R, et al. Rhythm-monitoring strategy and arrhythmia recurrence in atrial fibrillation ablation trials: a systematic review. CJC Open. 2022;4:488–96.CrossRefPubMedPubMedCentral Unni RR, Prager RT, Odabashian R, et al. Rhythm-monitoring strategy and arrhythmia recurrence in atrial fibrillation ablation trials: a systematic review. CJC Open. 2022;4:488–96.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Oral H, Veerareddy S, Good E, et al. Prevalence of asymptomatic recurrences of atrial fibrillation after successful radiofrequency catheter ablation. J Cardiovasc Electrophysiol. 2004;15:920–4.CrossRefPubMed Oral H, Veerareddy S, Good E, et al. Prevalence of asymptomatic recurrences of atrial fibrillation after successful radiofrequency catheter ablation. J Cardiovasc Electrophysiol. 2004;15:920–4.CrossRefPubMed
21.
Zurück zum Zitat Verma A, Champagne J, Sapp J, et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med. 2013;173:149–56.CrossRefPubMed Verma A, Champagne J, Sapp J, et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med. 2013;173:149–56.CrossRefPubMed
22.
Zurück zum Zitat Klemm HU, Ventura R, Rostock T, et al. Correlation of symptoms to ECG diagnosis following atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2006;17:146–50.CrossRefPubMed Klemm HU, Ventura R, Rostock T, et al. Correlation of symptoms to ECG diagnosis following atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2006;17:146–50.CrossRefPubMed
23.
Zurück zum Zitat Hindricks G, Piorkowski C, Tanner H, et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation. 2005;112:307–13.CrossRefPubMed Hindricks G, Piorkowski C, Tanner H, et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation. 2005;112:307–13.CrossRefPubMed
24.
Zurück zum Zitat Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120–9.CrossRefPubMed Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120–9.CrossRefPubMed
25.
Zurück zum Zitat Ortiz-Cartagena I, Gotay AO, Acevedo J. Cost effectiveness of oral anticoagulation therapy for non-valvular atrial fibrillation patients: warfarin versus the new oral anticoagulants rivaroxaban, dabigatran and apixaban. J Am Coll Cardiol. 2018;71:490–490.CrossRef Ortiz-Cartagena I, Gotay AO, Acevedo J. Cost effectiveness of oral anticoagulation therapy for non-valvular atrial fibrillation patients: warfarin versus the new oral anticoagulants rivaroxaban, dabigatran and apixaban. J Am Coll Cardiol. 2018;71:490–490.CrossRef
26.
Zurück zum Zitat Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. J Arrhythm. 2017;33:369–409.CrossRefPubMedPubMedCentral Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. J Arrhythm. 2017;33:369–409.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Benjamin EJ, Al-Khatib SM, Desvigne-Nickens P, et al. Research priorities in the secondary prevention of atrial fibrillation: A National Heart, Lung, and Blood Institute virtual workshop report. J Am Heart Assoc. 2021;10:e021566.CrossRefPubMedPubMedCentral Benjamin EJ, Al-Khatib SM, Desvigne-Nickens P, et al. Research priorities in the secondary prevention of atrial fibrillation: A National Heart, Lung, and Blood Institute virtual workshop report. J Am Heart Assoc. 2021;10:e021566.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Zado ES, Pammer M, Parham T, et al. “As Needed” nonvitamin K antagonist oral anticoagulants for infrequent atrial fibrillation episodes following atrial fibrillation ablation guided by diligent pulse monitoring: a feasibility study. J Cardiovasc Electrophysiol. 2019;30:631–8.CrossRefPubMed Zado ES, Pammer M, Parham T, et al. “As Needed” nonvitamin K antagonist oral anticoagulants for infrequent atrial fibrillation episodes following atrial fibrillation ablation guided by diligent pulse monitoring: a feasibility study. J Cardiovasc Electrophysiol. 2019;30:631–8.CrossRefPubMed
29.
Zurück zum Zitat Pothineni NVK, Amankwah N, Santangeli P, et al. Continuous rhythm monitoring-guided anticoagulation after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2021;32:345–53.CrossRefPubMed Pothineni NVK, Amankwah N, Santangeli P, et al. Continuous rhythm monitoring-guided anticoagulation after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2021;32:345–53.CrossRefPubMed
Metadaten
Titel
Accuracy of symptoms and pulse checking for detecting atrial fibrillation following catheter ablation
verfasst von
Timothy M. Markman
Carli Peters
Simone Tate
Gustavo S. Guandalini
Matthew C. Hyman
Robert D. Schaller
Gregory E. Supple
Michael P. Riley
Fermin Garcia
Saman Nazarian
David Lin
Sanjay Dixit
Andrew E. Epstein
David J. Callans
Francis E. Marchlinski
David S. Frankel
Publikationsdatum
12.09.2023
Verlag
Springer US
Erschienen in
Journal of Interventional Cardiac Electrophysiology / Ausgabe 3/2024
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-023-01643-4

Weitere Artikel der Ausgabe 3/2024

Journal of Interventional Cardiac Electrophysiology 3/2024 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.